Table 6.
Characteristics and medical costs of patients in the non-persistent group
| Total | BT-naïve | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ADL | IFX | UST | Sub total |
ADL | IFX | UST | Subtotal | ||
| Number of patients | 12 | 14 | 8 | 35 | 10 | 13 | 7 | 31 | |
| Average Age | 46.1 | 47.3 | 50.5 | 47.8 | 47.9 | 48.5 | 51.1 | 49.1 | |
| %Female | 8.3% | 21.4% | 12.5% | 14.3% | 10.0% | 23.1% | 14.3% | 16.1% | |
| Cost (pre) | ¥595 | ¥902 | ¥808 | ¥762 | ¥367 | ¥848 | ¥621 | ¥629 | |
| In 1000 JPY unit |
IP | ¥0 | ¥231 | ¥32 | ¥108 | ¥0 | ¥249 | ¥36 | ¥122 |
| OP | ¥332 | ¥259 | ¥448 | ¥324 | ¥81 | ¥198 | ¥232 | ¥166 | |
| RX | ¥263 | ¥412 | ¥328 | ¥330 | ¥286 | ¥401 | ¥353 | ¥341 | |
| Cost increase | ¥1504 | ¥2507 | ¥1828 | ¥1937 | ¥1620 | ¥2608 | ¥2254 | ¥2126 | |
| In 1000 JPY unit |
IP | ¥170 | ¥933 | ¥362 | ¥511 | ¥204 | ¥1005 | ¥414 | ¥577 |
| OP | ¥932 | ¥1749 | ¥1638 | ¥1395 | ¥946 | ¥1756 | ¥2021 | ¥1499 | |
| RX | ¥402 | - ¥175 | - ¥172 | ¥31 | ¥470 | - ¥153 | - ¥181 | ¥50 | |
ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs